Home > Publications database > ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors. > print

001     304998
005     20251005022951.0
024 7 _ |a 10.1016/j.annonc.2025.09.008
|2 doi
024 7 _ |a pmid:41016600
|2 pmid
024 7 _ |a 0923-7534
|2 ISSN
024 7 _ |a 1569-8041
|2 ISSN
024 7 _ |a altmetric:181744969
|2 altmetric
037 _ _ |a DKFZ-2025-01989
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a van Aken, E. S. M.
|b 0
245 _ _ |a ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1759230392_31253
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity data, leading to an absence of evidence-based guidelines.To address this, ESMO and ESTRO initiated a series of systematic reviews followed by a Delphi consensus process to develop multidisciplinary, evidence-based consensus statements regarding the safety of combining RT with such agents. The current publication describes the combination of RT with immune checkpoint inhibitors (ICIs), vascular endothelial growth factor (receptor) (VEGF(R)) inhibitors, or multitargeted tyrosine kinase inhibitors (TKIs). By systematically covering different drug classes and irradiated areas, 76 clinical scenarios were evaluated during two Delphi rounds with 20 international experts. Safety statements were developed for each scenario, based on the systematic literature reviews.A total of 5,921 records were screened during the systematic literature review process for ICIs, VEGF(R) inhibitors and multitargeted TKIs, and 159 reports were selected for inclusion in the final literature reviews and the database. During the two Delphi rounds, agreement was reached regarding the safety statements for 74 clinical scenarios.Generally, the expected toxicity of combining RT with ICIs is low, particularly for PD-(L)1 inhibitors. For most combinations with VEGF(R) inhibitors and multitargeted TKIs, exercising caution is recommended. The evidence-based safety statements developed during this comprehensive project, provide practical guidance on combining RT with targeted cancer therapies and immunotherapy.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Consensus statements
|2 Other
650 _ 7 |a Immune checkpoint inhibitors
|2 Other
650 _ 7 |a Radiotherapy
|2 Other
650 _ 7 |a Systematic review
|2 Other
650 _ 7 |a Toxicity
|2 Other
650 _ 7 |a Tyrosine kinase inhibitors
|2 Other
700 1 _ |a Devnani, B.
|b 1
700 1 _ |a Prelaj, A.
|b 2
700 1 _ |a Castelo-Branco, L.
|b 3
700 1 _ |a Marijnen, C. A. M.
|b 4
700 1 _ |a Martins-Branco, D.
|b 5
700 1 _ |a Gambacorta, M. A.
|b 6
700 1 _ |a Lamarca, A.
|b 7
700 1 _ |a Harrington, K.
|b 8
700 1 _ |a Minniti, G.
|b 9
700 1 _ |a Hecht, M.
|b 10
700 1 _ |a Papamichael, D.
|b 11
700 1 _ |a Krause, M.
|0 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
|b 12
|u dkfz
700 1 _ |a Cathomas, R.
|b 13
700 1 _ |a Lindberg, K.
|b 14
700 1 _ |a O'Cathail, S. M.
|b 15
700 1 _ |a Nestle, U.
|b 16
700 1 _ |a Barriuso, J.
|b 17
700 1 _ |a Nowicki, S.
|b 18
700 1 _ |a Rödel, C.
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Boot, P.
|b 20
700 1 _ |a Belka, C.
|b 21
700 1 _ |a Ricardi, U.
|b 22
700 1 _ |a Lordick, F.
|b 23
700 1 _ |a De Ruysscher, D.
|b 24
700 1 _ |a Pentheroudakis, G.
|b 25
700 1 _ |a de Jong, M. C.
|b 26
700 1 _ |a Gandhi, A. K.
|b 27
773 _ _ |a 10.1016/j.annonc.2025.09.008
|g p. S0923753425047192
|0 PERI:(DE-600)2003498-2
|p nn
|t Annals of oncology
|v nn
|y 2025
|x 0923-7534
909 C O |o oai:inrepo02.dkfz.de:304998
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN ONCOL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF >= 50
|0 StatID:(DE-HGF)9950
|2 StatID
|b ANN ONCOL : 2022
|d 2025-01-07
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK Koordinierungsstelle Dresden
|x 0
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK Koordinierungsstelle Frankfurt
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21